Erectile Dysfunction - Pipeline Insight, 2024

This “Erectile dysfunction - Pipeline Insight, 2024,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Erectile dysfunction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Erectile dysfunction Understanding

Erectile dysfunction: Overview

Erectile dysfunction (ED), formerly termed impotence, is defined as the failure to achieve or maintain a rigid penile erection suitable for satisfactory sexual intercourse. While no specific time period is part of this definition, some have suggested that the condition needs to persist for six months. It is a common condition in men aged over 40 years, with the prevalence increasing steeply with age and other co-morbidities. Erectile dysfunction can be a symptom of a wide range of underlying pathologies and is an important but underutilized cardiovascular risk factor. Any disease process which affects penile arteries, nerves, hormone levels, smooth muscle tissue, corporal endothelium, or tunica albuginea can cause erectile dysfunction. It is generally acknowledged that erectile dysfunction is closely related to cardiovascular disease, diabetes mellitus, hyperlipidemia, and hypertension, among other disorders. Endothelial dysfunction appears to be the other common pathway in these patients. There are no specific tests absolutely required for the initial evaluation of ED, but many physicians will order routine blood testing to include a complete blood count and electrolytes as well as baseline renal and liver function tests, HgbA1c to screen for diabetes mellitus, and a lipid profile. Penile Biothesiometry is a simple office screening test for penile neuropathy using skin vibrational threshold sensitivity. Initial treatment involves improving general health status through lifestyle modifications. This not only improves erectile function but reduces cardiovascular risk.

Erectile dysfunction - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Erectile dysfunction pipeline landscape is provided which includes the disease overview and Erectile dysfunction treatment guidelines. The assessment part of the report embraces, in depth Erectile dysfunction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Erectile dysfunction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• In September 2021, Intel Genx Corp. announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction and benign prostatic hyperplasia, Aquestive Therapeutics, has entered into a definitive license and supply agreement with an undisclosed leading men’s healthcompany.
• CF602, being developed by Can-Fite, has shown efficacy in the treatment of erectile dysfunction.

Erectile dysfunction Emerging Drugs Chapters

This segment of the Erectile dysfunction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Erectile dysfunction Emerging Drugs

MED3000: Futura Medical MED3000 is a unique formulation of DermaSys® using volatile components specifically tailored for the treatment of ED. MED3000 works through a unique evaporative mode of action. MED3000’s combination of volatile components creates a novel action that stimulates nerve sensors in the highly innervated glans penis by a cooling and recovery warming effect, rapidly leading to smooth muscle relaxation, tumescence and erection as shown on the diagram below. MED3000 generates a rapid cooling and recovery warming action, promoting a sensory stimulation of the nerves on the glans penis leading to fast smooth muscle relaxation, tumescence and erection. MED3000 is supported by efficacy and safety data from a range of studies including the completed Phase IIIstudy.

TPN171H: Vigonvita Life Sciences TPN171H is a novel, potent and selective phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH) and erectile dysfunction. PDE5 breaks down c GMP, a molecule that causes blood vessels to relax and widen (vasodilation), thereby reducing blood pressure. As such, by blocking PDE5, TPN171H is thought to indirectly increase cGMP levels, support vasodilation, and ultimately reduce pulmonary blood pressure and improve heart function, allowing patients to become more active. Given that the therapy was reported to be selective and have a longer-lasting effect in animal models than the approved oral PDE5 inhibitor sildenafil, it may have a more favorable safety and pharmacological profile. Vigonvita Life Sciences has initiated a Phase III study to evaluate the efficacy and safety of TPN171H in men witherectiledysfunction.

IPED2015: Initiator Pharma IP2015 strengthens the natural erection response by having a dual-action, both a central effect initiating erection and a peripheral effect potentiating erection through smooth muscle relaxation. IP2015 is aimed for treatment of erectile dysfunction in patients who have erectile dysfunction due to metabolic syndrome and diabetes denoted organic erectile dysfunction. IPED2015 drug program has successfully demonstrated efficacy in a Clinical Phase IIa Proof-of-Concept study to treat patients who suffer from organic erectile dysfunction (ED) that do not respond to the currently marketed drugs in the PDE5i class. With the help of a competent research team, the Initiator’s main business concept is to further develop the existing drug candidate IP2015 through successful Phase II studies, which will lay the foundation for a potential exit or partnership agreement.

Erectile dysfunction: Therapeutic Assessment

This segment of the report provides insights about the different Erectile dysfunction drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Erectile dysfunction

There are approx. 22+ key companies which are developing the therapies for Erectile dysfunction. The companies which have their Erectile dysfunction drug candidates in the most advanced stage, i.e. Phase III include, Futura Medical.

Phases

This report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Erectile dysfunction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Erectile dysfunction: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Erectile dysfunction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Erectile dysfunction drugs.

Erectile dysfunction Report Insights

• Erectile dysfunction Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Erectile dysfunction Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Erectile dysfunction drugs?
• How many Erectile dysfunction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Erectile dysfunction?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Erectile dysfunction therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Erectile dysfunction and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vigonvita Life Sciences
• Futura Medical Developments
• Initiator Pharma
• Pharmicell Co., Ltd.
• BioIntegrate
• Biozeus Biopharmaceutical
• Can-Fite Biopharma
• Fabre-Kramer Pharmaceuticals
• Humanetics Pharmaceuticals
• Hemostemix Inc.,
• Ilgen Bio
• Aquestive Therapeutics
• MicroCures
• Dicot AB
• CURE Pharmaceutical
• IX BIOPHARMA
• Exopharm
• Oncotelic Therapeutics
• Blue Cell Therapeutics
• S1 Biopharma

Key Products

• TPN171H
• MED3000
• IPED2015
• IP2018
• Cellgram-ED
• Dual StimTherapy
• BZ371A
• CF-602
• FKK01PD
• BIO 300
• ACP-01
• HUMAN FUSION PROTEIN ILG-F
• Orexa

This product will be delivered within 1-3 business days.